Clinical Trial Update: Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating vaccination with dendritic cells loaded with peptides for recurrent malignant glioma; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Vaccination-Dendritic Cells With Peptides (dendritic cell vaccine (peptide-loaded))

Snippet

Sponsor: Frank Lieberman | Conditions: Malignant Glioma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-05-11